生物
胶质瘤
干细胞
癌症研究
基因
基因复制
遗传学
作者
Zhicheng He,Qing Liu,Kaidi Yang,Cong Chen,Xiao‐Ning Zhang,Wenying Wang,Hui Zeng,Bin Wang,Yuqi Liu,Min Luo,Lei Li,Qin Niu,Huimin Lu,Tao Luo,Xiaohong Yao,Haitao Guo,Jia-Le Ji,Mianfu Cao,Yu Shi,Yi‐Fang Ping
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2022-02-24
卷期号:533: 215605-215605
被引量:15
标识
DOI:10.1016/j.canlet.2022.215605
摘要
Although the tumorigenic potential of glioma stem cells (GSCs) is associated with multiple molecular alterations, the gene amplification status of GSCs has not been elucidated. Overexpression of HomeoboxA5 (HOXA5) is associated with increased glioma malignancy. In this study, we identify the gene amplification and protein overexpression of HOXA5 in GSCs and its function in regulating GSC maintenance and the downstream transcriptional effector, to explore the significance of HOXA5 amplification/overexpression for GSC identification and prognostic determination. The HOXA5 gene is significantly amplified in glioblastoma (GBM) and is an independent prognostic factor for predicting worse patient outcomes. Specifically, HOXA5 gene amplification and the resultant protein overexpression are correlated with increased proportions of GSCs and enhanced self-renewal/invasiveness of these cells. Disruption of HOXA5 expression impairs GSC survival and GBM tumor propagation. Mechanistically, HOXA5 directly binds to the promoter region of protein tyrosine phosphatase receptor type Z1 (PTPRZ1), thereby upregulating this gene for GSC maintenance. Suppression of PTPRZ1 largely compromises the pro-tumoral effect of HOXA5 on GSCs. In summary, HOXA5 amplification serves as a genetic biomarker for predicting worse GBM outcome, by enhancing PTPRZ1-mediated GSC survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI